

CHEMESIS INTERNATIONAL INC. ANNOUNCES APPOINTMENT OF NEW CHIEF FINANCIAL OFFICER & OPTION GRANT

September 7, 2018 – Vancouver, BC – Chemesis International Inc. (CSE: <u>CSI</u>) (OTC: <u>CADMF</u>) (the "Company" or "Chemesis"), is pleased to announce the addition of Mr. Eli Dusenbury as the Company's new Chief Financial Officer and the granting of options.

Mr. Dusenbury has extensive experience in public accounting providing services to both public and private sector clients reporting in Canada and in the U.S., over a broad range of industries, including but not limited to technology, agriculture, engineering, mining & exploration, manufacturing and financing. Mr. Dusenbury obtained his Chartered Professional Accountant designation in 2011, and holds a BBA in business and accounting from Capilano University.

The Company wishes to thank Mr. Lee for his service as CFO during the Company's growth and wishes him the best in his future endeavours.

The Company announces that on September 14, 2018 it has granted an aggregate of 150,000 incentive stock options to a consultant of the Company. The options are exercisable at \$1.00 per share for a one-year term. The Company announces an additional stock option grant of 200,000 incentive stock options to an Officer of the Company. The options are exercisable at \$1.74 CAD for a five-year term. There are also no vesting provisions for either option grant other than a four-month hold period from the date of the grant in accordance with the Company's Stock Option Plan.

About Chemesis International Inc.

Chemesis International Inc. is a vertically integrated global leader in the cannabis industry, currently operating within Puerto Rico, and California.

Chemesis is developing a strong foothold in key markets, from cultivation, to manufacturing, distribution, and retail. Chemesis has facilities in both Puerto Rico and California, allowing for cost effective production and distribution of its products. In addition, Chemesis leverages exclusive brands and partnerships and uses the highest quality extraction methods, to provide consumers with quality cannabis products.

Chemesis will add shareholder value by exploring opportunities in emerging markets while consistently delivering quality product to its consumers from seed to sale.

ON BEHALF OF THE BOARD OF DIRECTORS

Edgar Montero
CEO and Director

INVESTOR RELATIONS:

ir@chemesis.com www.chemesis.com 1 (604) 398-3378

Chemesis, Inc. (CSE: CSI) (OTC: CADMF)





Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company's business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release



Chemesis, Inc. (CSE: CSI) (OTC: CADMF)